Movement Alert|CVS Health Falls 3.08% in Pre-Market Trading, Store Expansion Fails to Offset 340B Earnings Worries

Market Focus
10/09

On October 9, CVS Health fell 3.08% in pre-market trading, trading at $85.29 per share, with turnover of $556,000.

The positive news of the company opening its first pharmacy-focused store in Boston failed to support the stock, as market attention shifted to earnings pressure from the 340B drug discount program. BofA Securities maintained a Buy rating but lowered its price target from $120 to $110, pointing to greater earnings risk in 2027. The proposed changes to 340B reimbursement rules could create an EBIT headwind of $600 million to $700 million in 2027. While the company can offset these headwinds through Aetna margin recovery and other channels, short-term valuation pressure remains evident.

CVS Health Corporation provides health services in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, while its Retail/LTC segment operates approximately 9,900 retail locations and 1,200 MinuteClinic locations. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10